IL2 and melanoma: Intralesional IL2 likely potentiates the Th1-promoting ability of TLR7 activation, which is supported by data revealing that the peripheral CD4+/CD8+ T cell ratio following treatment with imiquimod and intralesional IL2 is significantly increased in peripheral blood mononuclear cell samples (PBMC) of melanoma patients [56].